Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Fibrocell Science, Inc., an autologous cell therapy company, focuses on developing various treatments for skin diseases and conditions with unmet medical needs. The company, through its proprietary autologous fibroblast technology, Fibrocell, develops biologic solutions and medical applications of azficel-T for restrictive burn scarring and vocal cord scarring conditions; and biologic products for patients with rare genetic skin and tissue disorders. It has collaboration agreements with Intrexon Corporation for using genetically-modified fibroblasts for treating rare and serious skin, and connective tissue diseases; and University of California, Los Angeles to focus on skin-derived stem cells and other ways to convert skin cells to other cell types. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was founded in 1995 and is headquartered in Exton, Pennsylvania.
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||234.48%||Sales Growth - Q/Q||246.43%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-48.97%||ROE||-90.53%||ROI|
|Current Ratio||5.79||Quick Ratio||5.7||Long Term Debt/Equity||Debt Ratio||0.27|
|Gross Margin||-407.93%||Operating Margin||-7871.34%||Net Profit Margin||-6148.17%||Dividend Payout Ratio|
|Cash From Financing Activities||150 K||Cash From Investing Activities||-110 K||Cash From Operating Activities||-4.24 M||Gross Profit||50 K|
|Net Profit||-8.53 M||Operating Profit||-6.86 M||Total Assets||41.18 M||Total Current Assets||34.93 M|
|Total Current Liabilities||6.03 M||Total Debt||Total Liabilities||18.9 M||Total Revenue||190 K|
|High 52 week||4.8||Low 52 week||1.5||Last close||2.01||Last change||4.15%|
|RSI||56.35||Average true range||0.15||Beta||0.53||Volume||94.25 K|
|Simple moving average 20 days||2.85%||Simple moving average 50 days||7.42%||Simple moving average 200 days||-8.41%|
|Performance Week||-0.99%||Performance Month||4.15%||Performance Quart||-2.43%||Performance Half||1.01%|
|Performance Year||-33.55%||Performance Year-to-date||34%||Volatility daily||3.31%||Volatility weekly||7.4%|
|Volatility monthly||15.17%||Volatility yearly||52.56%||Relative Volume||107.4%||Average Volume||110.19 K|
|New High||New Low|
2019-04-17 09:14:00 | These 2 Biotech Stocks Are No Longer 'Off the Radar'
2019-04-17 07:48:11 | Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal
2019-04-16 19:26:11 | ProQR Initiates Dosing in Phase II/III Eye Disorder Study
2019-04-16 10:59:02 | Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises
2019-04-15 13:22:55 | Fibrocell signs $135M deal to advance therapy for 'butterfly children'
2019-02-06 08:00:00 | Fibrocell to Present at 21st Annual BIO CEO & Investor Conference
2019-01-16 08:00:00 | Fibrocell to Present at Phacilitate Leaders World 2019
2018-12-04 14:16:31 | What Kind Of Shareholders Own Fibrocell Science Inc NASDAQ:FCSC?
2018-11-19 08:30:00 | Market Trends Toward New Normal in Fibrocell Science, Sears Hometown and Outlet Stores, Apellis Pharmaceuticals, Sigma Labs, Highpower International, and Nicholas Financial — Emerging Consolidated Expectations, Analyst Ratings
2018-11-13 08:00:00 | Fibrocell Reports Third Quarter 2018 Financial Results and Recent Highlights
2018-11-09 14:08:07 | Intrexon XON Reports Narrower-Than-Expected Loss in Q3
2018-10-25 08:00:00 | Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007
2018-09-26 08:00:00 | Fibrocell to Present at Upcoming Industry and Investor Conferences
2018-08-09 08:00:00 | Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights
2018-08-09 06:30:00 | Fibrocell Science, Inc. to Host Earnings Call
2018-07-31 17:09:09 | What's in Store for Intrexon XON This Earnings Season?
2018-07-25 07:35:00 | Free Technical Research on Evolus and Three More Generic Drugs Equities
2018-07-05 16:05:00 | Fibrocell Announces Closing of $4.0 Million Registered Direct Offering
2018-07-02 11:05:35 | Chester County gene therapy company expects $4M direct from direct stock offering
2018-07-02 09:00:00 | Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-Market
2018-06-01 08:16:41 | Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO
2018-06-01 07:39:25 | Chester County gene therapy company completes $6M stock sale
2018-06-01 06:57:10 | Fibrocell Science FCSC Sees Hammer Chart Pattern: Time to Buy?
2018-05-31 16:05:00 | Fibrocell Announces Closing of $6.0 Million Registered Direct Offering
2018-05-29 09:20:00 | Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-Market
2018-05-24 08:56:09 | Fibrocell Announces One-for-Five Reverse Stock Split
2018-05-21 08:59:20 | Benzinga Pro's 5 Stocks To Watch Today
2018-05-17 08:27:58 | Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More
2018-05-10 08:00:00 | Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights
2018-05-02 10:54:02 | What's in Store for Intrexon XON This Earnings Season?
2018-04-18 08:00:00 | Fibrocell Announces Review of Strategic Alternatives
2018-03-19 08:00:00 | Fibrocell Reports 2017 Financial Results and Recent Highlights
2018-03-19 07:42:31 | Does Fibrocell Science Inc’s NASDAQ:FCSC Past Performance Indicate A Stronger Future?
2018-03-19 06:30:00 | Fibrocell Science, Inc. to Host Earnings Call